No matches

77 search results for: patient burden

Content temporarily unavailable

Gap in Care Leads to Progression of Fibrosis in EoE

Dr. Evan Dellon discusses the clinical implications of gaps in medical care on the risk of fibrotic progression in EoE.

Content temporarily unavailable

UEG 2025 | Understanding Type 2 Inflammation in EoE: A Case-Based Discussion

Profs. Greuter, Savarino, and Giordano discuss best practices for EoE identification, multidimensional EoE assessment, and transition of care.

Content temporarily unavailable

ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions

The ERS-ISIAN 2025 symposium, featuring Prof. Vibeke Backer and Prof. Sietze Reitsma, titled "Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions," will delve into the complexities of the role of type 2 inflammation in CRSwNP.

Content temporarily unavailable

UEGW 2024 | Something to Chew On: Exploring Biologics in EoE Management

Prof. Salvatore Oliva and Dr. Milli Gupta discuss the importance of long-term care, multidimensional assessment, and the latest data for biologics.

Content temporarily unavailable

World Anosmia Awareness Day

Explore our educational resources about loss of smell and the role of type 2 inflammation in CRSwNP, featuring expert insights from Profs. Wytske Fokkens and Joaquim Mullol.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Costa RicaChange country/region